KTTA
Pasithea Therapeutics Corp
NASDAQ: KTTA · HEALTHCARE · BIOTECHNOLOGY
$0.69
+0.87% today
Updated 2026-04-30
Market cap
$17.21M
P/E ratio
—
P/S ratio
42.15x
EPS (TTM)
$-2.91
Dividend yield
—
52W range
$0 – $2
Volume
0.4M
Pasithea Therapeutics Corp (KTTA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $15062.00 | $486559.00 | $486559.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | +3130.4% | +0.0% | -100.0% | — |
| Cost of revenue | — | $17275.00 | $5094.00 | $648454.00 | $649029.00 | $662585.00 |
| Gross profit | — | $-2213.00 | $-5094.00 | $-648454.00 | $-649029.00 | $-662585.00 |
| Gross margin | — | -14.7% | -1.0% | -133.3% | — | — |
| R&D | — | $0.00 | $2.67M | $8.10M | $7.20M | $7.98M |
| SG&A | — | $4.51M | $9.92M | $7.88B | $7.05M | $12.88M |
| Operating income | $-61476.00 | $-4.51M | $-12.59M | $-15.98M | $-14.25M | $-20.86M |
| Operating margin | — | -29925.7% | -2587.3% | -3284.2% | — | — |
| EBITDA | $-40980.00 | $-4.51M | $-11.72M | $-15.33M | $-13.60M | $-20.19M |
| EBITDA margin | — | -29916.6% | -2409.3% | -3150.9% | — | — |
| EBIT | $-102456.00 | $-4.51M | $-11.73M | $-15.98M | $-14.25M | $-20.86M |
| Interest expense | $0.00 | $508.00 | $102.00 | — | — | — |
| Income tax | $-61476.00 | $508.00 | $-879971.00 | $453.91M | — | — |
| Effective tax rate | 50.0% | -0.0% | 5.9% | 103.6% | 0.0% | 0.0% |
| Net income | $-61476.00 | $-2.17M | $-13.94M | $-15.96M | $-13.90M | $-20.43M |
| Net income growth (YoY) | — | -3435.6% | -541.2% | -14.5% | +12.9% | -46.9% |
| Profit margin | — | -14430.5% | -2864.3% | -3280.5% | — | — |